Oesophageal cancer.
Yang H, Wang F, Hallemeier CL, Lerut T, Fu J.
Lancet. 2024 Nov 16;404(10466):1991-2005. doi: 10.1016/S0140-6736(24)02226-8.
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K.
Nat Rev Clin Oncol. 2021 Aug;18(8):473-487. doi: 10.1038/s41571-021-00492-2. Epub 2021 Mar 31.
Tumor implantation following percutaneous endoscopic gastrostomy insertion for head and neck and oesophageal cancer: Review of the literature.
Rowell NP.
Head Neck. 2019 Jun;41(6):2007-2015. doi: 10.1002/hed.25652. Epub 2019 Jan 25.
Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia.
Fang K, Sun M, Leng Z, Chu Y, Zhao Z, Li Z, Zhang Y, Xu A, Zhang Z, Zhang L, Chen T, Xu M.
J Exp Clin Cancer Res. 2023 Mar 28;42(1):73. doi: 10.1186/s13046-023-02623-2.
Palliation of malignant dysphagia from oesophageal cancer. Rotterdam Oesophageal Tumor Study Group.
Siersema PD, Dees J, van Blankenstein M.
Scand J Gastroenterol Suppl. 1998;225:75-84. doi: 10.1080/003655298750027272.
Improving individualised therapies in localised gastro-oesophageal adenocarcinoma.
Svrcek M, Voron T, André T, Smyth EC, de la Fouchardière C.
Lancet Oncol. 2024 Sep;25(9):e452-e463. doi: 10.1016/S1470-2045(24)00180-3.
Neoadjuvant treatment in oesophageal cancer: the needs for future trials. The Rotterdam Esophageal Tumor Study Group.
Kok TC, Tilanus HW.
Eur J Surg Oncol. 1996 Aug;22(4):323-5. doi: 10.1016/s0748-7983(96)90066-9.
Oesophageal cavernous haemangioma.
Imenpour H, Muti M, Pastorino G.
Pathologica. 2018 Mar;110(1):72-74.
Integrated machine learning developed a prognosis-related gene signature to predict prognosis in oesophageal squamous cell carcinoma.
Tang P, Li B, Zhou Z, Wang H, Ma M, Gong L, Qiao Y, Ren P, Zhang H.
J Cell Mol Med. 2024 Nov;28(21):e70171. doi: 10.1111/jcmm.70171.
Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma.
Gao W, Liu S, Wu Y, Wei W, Yang Q, Li W, Chen H, Luo A, Wang Y, Liu Z.
EBioMedicine. 2024 Jul;105:105177. doi: 10.1016/j.ebiom.2024.105177. Epub 2024 Jun 25.
